IRIS
MINARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.000
NA - Nord America 911
AS - Asia 393
AF - Africa 24
SA - Sud America 3
OC - Oceania 2
Totale 2.333
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 906
IT - Italia 407
IE - Irlanda 211
CN - Cina 172
SE - Svezia 160
SG - Singapore 141
DE - Germania 37
AT - Austria 33
FI - Finlandia 32
FR - Francia 31
CI - Costa d'Avorio 23
IN - India 23
CZ - Repubblica Ceca 18
HK - Hong Kong 18
TR - Turchia 16
GB - Regno Unito 14
NL - Olanda 12
RU - Federazione Russa 8
BE - Belgio 6
CA - Canada 5
JP - Giappone 5
LU - Lussemburgo 5
UA - Ucraina 5
IR - Iran 4
RO - Romania 4
AR - Argentina 3
ES - Italia 3
MK - Macedonia 3
PK - Pakistan 3
AU - Australia 2
BG - Bulgaria 2
DK - Danimarca 2
ID - Indonesia 2
IL - Israele 2
MD - Moldavia 2
PL - Polonia 2
VN - Vietnam 2
HR - Croazia 1
HU - Ungheria 1
KR - Corea 1
LT - Lituania 1
MY - Malesia 1
PH - Filippine 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.333
Salva come PNG Salva come JPEG
Città #
Dublin 206
Chandler 200
Parma 111
Boardman 96
Ashburn 90
Singapore 90
Ann Arbor 84
Shanghai 73
Milan 49
Vienna 32
New York 31
Beijing 27
Chicago 27
Marseille 27
Abidjan 23
Princeton 22
Verona 22
Bologna 20
Dearborn 16
West Jordan 16
Helsinki 15
Bremen 14
Brno 13
Hong Kong 12
Izmir 11
Des Moines 10
Los Angeles 10
Santa Clara 10
Wilmington 10
Amsterdam 9
Munich 9
London 8
Pune 8
Dallas 7
Fremont 7
Jinan 7
Modena 7
Ravenna 7
Auburn 6
Brussels 6
Kolkata 6
Pavia 6
Redmond 6
Rome 6
Woodbridge 6
Bolzano 5
Changsha 5
Nanchang 5
Nanjing 5
Seattle 5
Shenyang 5
Bottanuco 4
Busseto 4
Cascina 4
Central 4
Ferrara 4
Hefei 4
Jacksonville 4
Olomouc 4
Salsomaggiore Terme 4
Trento 4
Wayne 4
Buenos Aires 3
Casalgrande 3
Castellarano 3
Coimbatore 3
Guangzhou 3
Houston 3
Istanbul 3
Kunming 3
Kyiv 3
Lonato 3
Norwalk 3
Redwood City 3
Rubiera 3
San Giuliano Milanese 3
Alcamo 2
Ayr 2
Bagnolo in Piano 2
Boston 2
Brusaporto 2
Candiac 2
Carpenedolo 2
Chiari 2
Chisinau 2
Desio 2
Dong Ket 2
Fairfield 2
Florence 2
Frankfurt am Main 2
Genoa 2
Gioia Tauro 2
Hayamiya 2
Hebei 2
Karak 2
Leawood 2
Madrid 2
Marino 2
Menteng 2
Minerbio 2
Totale 1.642
Salva come PNG Salva come JPEG
Nome #
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 122
Evidence fo Epigenetic Abnormalities of the Androgen Receptor Gene in Foreskin from Children with Hypospadias 118
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 106
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 81
A novel mutation in the nr0b1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children. 77
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 76
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 74
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 73
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 72
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 70
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 69
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 69
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 65
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 65
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 63
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 62
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 62
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 61
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 59
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 54
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 53
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 52
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 51
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 50
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 47
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 46
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 45
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 42
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 40
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 39
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 38
227P Sexual dimorphism in immune profile of early and advanced NSCLC 36
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 36
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 34
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 32
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 28
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 27
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 27
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 26
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 22
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 22
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 15
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 14
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 13
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 13
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 13
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 12
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 10
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 9
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 9
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 8
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 8
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 8
Totale 2.423
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.796
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.796
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020103 0 0 0 3 6 15 20 7 12 21 14 5
2020/2021102 3 5 2 5 3 5 12 10 20 8 14 15
2021/2022215 19 8 10 16 11 2 43 10 17 3 20 56
2022/2023849 67 84 37 73 83 87 15 64 242 7 61 29
2023/2024656 30 24 15 28 58 89 62 35 36 70 86 123
2024/2025390 101 105 144 40 0 0 0 0 0 0 0 0
Totale 2.423